Abstract
The negative results of the IV immunoglobulin trial in mild to moderate Alzheimer disease (AD) dementia1 raised a number of questions for the AD immunotherapy field. Do naturally occurring antibodies have advantages over monoclonal antibodies; if so, how can the advantages be leveraged? What dose and frequency is necessary for benefit? What stage of the AD continuum is optimal for pooled immunoglobulin therapy?
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
